Endpoints
cancer, tumor
TUMOR, CANCER, RESIDUAL CANCER, SECONDARY, REGRESSION, PATHOLOGY
The primary objectives were pathological response rate (ypRR with tumor regression score, TRS ≤2), and safety/tolerability of the combination. The tumor regression score (TRS) was based on pathology review, and recorded for each patient according to the following categories: 0 (complete response: no viable cancer cells), 1 (near complete response: single cells or rare small groups of cancer cells), 2 (partial response: residual cancer showing evident tumor regression, but more than single cells or rare small groups of cancer cells), or 3 (poor or no response: extensive residual cancer and no evident tumor regression). The secondary objectives were to evaluate the antitumor activity of the combination as determined by objective response rate (ORR), disease‐free survival (DFS), and overall survival (OS). This single institutional study was fully approved by the institutional review board (IRB) of the University Kansas Medical Center with Trial registration – 